1-AdaMantanethylaMine

Bezeichnung:1-AdaMantanethylaMine

CAS-Nr13392-28-4

Englisch Name:1-AdaMantanethylaMine

CBNumberCB7122907

SummenformelC12H21N

Molgewicht179.3

MOL-Datei13392-28-4.mol

1-AdaMantanethylaMine physikalisch-chemischer Eigenschaften

Siedepunkt	248°C
Dichte	1.033
Flammpunkt	99°C
storage temp.	Store at -20°C
Löslichkeit	Soluble in DMSO
pka	11.17±0.29(Predicted)
CAS Datenbank	13392-28-4(CAS DataBase Reference)
NIST chemische Informationen	1-Adamantanemethylamine, «alpha»-methyl-(13392-28-4)

Sicherheit

HazardClass	IRRITANT
HS Code	2902190000
Giftige Stoffe Daten	13392-28-4(Hazardous Substances Data)

Gefahreninformationscode (GHS)

1-AdaMantanethylaMine Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Rimantadine act by blocking the M2 ion channel which is required for uptake of protons into the interior of the virus to permit acid-promoted viral uncoating (decapsidation).
Definition
ChEBI: 1-(1-adamantyl)ethanamine is an alkylamine.
Trademarks
Flumadine (Forest).
Allgemeine Beschreibung
Resistant variants of influenza type A have been recoveredfrom rimantadine-treated patients.Resistance with inhibitory concentrations increased morethan 100-fold have been associated with single nucleotidechanges that lead to amino acid substitutions in the transmembranedomain of M2. rimantadineshare cross-susceptibility and resistance.
Pharmazeutische Anwendungen
An analog of amantadine, supplied as the hydrochloride for oral administration.
Mechanism of action
Rimantadine hydrochloride (α-methyl-1-adamantanemethylamine hydrochloride) is a synthetic adamatane derivative that is structurally and pharmacologically related to amantadine. It appears to be more effective than amantadine hydrochloride against influenza A, with fewer CNS side effects. Rimantadine hydrochloride is thought to interfere with virus uncoating by inhibiting the release of specific proteins. It may act by inhibiting RT or the synthesis of virus-specific RNA, but it does not inhibit virus adsorption or penetration. It appears to produce a virustatic effect early in the virus replication. It is used widely in Russia and Europe.
Pharmakokinetik
Oral absorption: >90%
C_max 100 mg oral (every 12 h): 0.4–0.5 mg/L after 2–6 h
Plasma half-life: c. 35 h
Volume of distribution: Very large
Plasma protein binding: c. 40%
Absorption and distribution
Single- and multiple-dose pharmacokinetic studies in elderly patients and young adults are remarkably similar. The steadystate concentration in nasal mucus develops by day 5 at a concentration approximately 1.5-fold higher than plasma.
Metabolism
In contrast to amantadine, rimantadine is extensively metabolized in the liver by hydroxylation and glucuronidation.
Excretion
Less than 20% is excreted unchanged in the urine and most of the breakdown products are excreted by this route. Thus, the plasma half-life is much less affected by renal dysfunction than that of amantadine.
Clinical Use
rimantadine is used for the treatment of diseases caused by influenza A strains.
Clinical Use
Prophylaxis and treatment of influenza A H1N1 infections Since prolonged administration is well tolerated by elderly patients, the drug is preferable to amantadine.
Nebenwirkungen
Rimantadine has significantly fewer side effects than amantadine at equivalent doses, perhaps because of differences in pharmacokinetics, since with equal doses the blood levels are considerably lower. CNS side effects are not significantly higher than placebo.

1-AdaMantanethylaMine Upstream-Materialien And Downstream Produkte

1-AdaMantanethylaMine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

13392-28-4, 1-AdaMantanethylaMine Verwandte Suche:

Send Inquriy